A pooled analysis of three trials evaluatinglarotrectinib monotherapy in 153 adult and pediatric patients with refractorycancers of various tumor histologies demonstrated an ORR of 79% and CR rate of 16%.86 Responses were durable, leading to a median PFS of 28.3 months.Entrectinib, which targets TRK proteins, as well as c-ROS oncogene1(ROS) and anaplastic lymphoma kinase(ALK), was studied in the STARTRK-1, STARTRK-2, and ALKA372-001trials. Here, ALK is linked to neoplasm.